Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Lefamulin targets ILF3 to overcome targeted therapy resistance in hepatocellular carcinoma

ABSTRACT: Lefamulin targets ILF3 to overcome targeted therapy resistance in hepatocellular carcinoma

PROVIDER: PRJNA1063444 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR27504384_1.fastq.gz	Fastqsanger.gz
	SRR27504384_2.fastq.gz	Fastqsanger.gz
	SRR27504385_1.fastq.gz	Fastqsanger.gz
	SRR27504385_2.fastq.gz	Fastqsanger.gz
	SRR27504386_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

Lefamulin targets ILF3 to overcome targeted therapy resistance in hepatocellular carcinoma []

Project description:Acquired resistance represents a critical clinical challenge to molecular targeted therapies such as tyrosine kinase inhibitors (TKIs) treatment in hepatocellular carcinoma (HCC). Therefore, it is urgent to explore new mechanisms and therapeutics that can overcome or delay resistance. Here, we identified a U.S. Food and Drug Administration (FDA)-approved pleuromutilin antibiotic that overcomes sorafenib resistance in HCC cell lines, cell line-derived xenograft (CDX) and hydrodynamic injection mouse models. We demonstrated that lefamulin targets and binds Interleukin Enhancer-binding Factor 3 (ILF3) to inhibit sorafenib-induced mitochondrial ribosomal protein L12 (MRPL12) upregulation. Mechanistically, lefamulin directly binds to Ala-99 of ILF3 and interferes with acetyltransferase general control non-depressible 5 (GCN5) and CREB binding protein (CBP) mediated acetylation of Lys-100, which disrupting the ILF3-mediated transcription of MRPL12 and subsequent mitochondrial biogenesis. Clinical data further confirmed that high ILF3 or MRPL12 expression was associated with poor survival and targeted therapy efficacy in HCC. Conclusively, our findings suggest that ILF3 is a potential therapeutic target for overcoming resistance to TKIs, and lefamulin may be a novel combination therapy strategy for HCC treatment with sorafenib and regorafenib.

2024-01-17 | GSE252987 | GEO

Lefamulin targets ILF3 to overcome targeted therapy resistance in hepatocellular carcinoma

2024-01-17 | GSE252988 | GEO

Lefamulin targets ILF3 to overcome targeted therapy resistance in hepatocellular carcinoma []

Project description:Lefamulin targets ILF3 to overcome targeted therapy resistance in hepatocellular carcinoma []

| PRJNA1063443 | ENA

RIP-seq using ILF3 antibodies to reveal RNAs that binds to ILF3 protein

Project description:RNA pulldown assay showed that lncRNA UBE2CP3 could bind to ILF3 protein. In order to further verify the interaction between ILF3 and UBE2CP3, RNA Immunoprecipitation (RIP) assay was performed to identify the RNAs that binds to ILF3 protein. RIP-seq data verifies the interaction between ILF3 and UBE2CP3. Interestingly, UBE2CP3 could also binds to 3'UTR of IGFBP7 mRNA. Mechanismly, lncRNA UBE2CP3 and 3' UTR of IGFBP7 could forms an double-stranded RNA. Then, the RNA duplex could interact with the Double-Stranded RNA-Binding Protein ILF3.

2021-05-03 | GSE163815 | GEO

Genome-wide binding sites of NF90/ILF3 in K562 erythroleukemia cells

Project description:We used ChIP-seq to characterize the genome-wide binding sites of NF90/ILF3 in K562 erythroleukemia cells.

2018-03-01 | E-MTAB-6042 | biostudies-arrayexpress

Knockdown of ILF2/ILF3 (NF45/NF90) in the gastric cancer cell line SGC7901

Project description:Our data showed that lncRNA ELF3-AS1 could bind on the exon1 of ELF3-201 to form a double-stranded RNA molecule. This double-stranded RNA could interact with ILF2/ILF3 complex. To explore the biofunction of the interaction between ELF3-AS1 and ILF2/ILF3 complex, loss-of-function studies regarding ILF2 and ILF3 were performed in SGC7901 cell line. RNA sequencing studies showed that knockdown of ILF3 significantly decreased ELF3-AS1, while knockdown of ILF2 significantly increased ELF3-AS1 and NF90 expression. Our data revealed that ILF2/ILF3 complex interacted with ELF3-AS1/ELF3 double-stranded RNA and regulated their transcripts stability.

2021-10-01 | GSE161544 | GEO

RIP-seq using ILF3 antibodies to reveal RNAs that binds to ILF3 protein

Project description:RIP-seq using ILF3 antibodies to reveal RNAs that binds to ILF3 protein

| PRJNA687674 | ENA

Explored the underlying mechanism by which ILF3 exerted carcinogenesis and its potential targets in MM

Project description:An RIP experiment was performed in ARP1 cell following the instructions of the article. ~5-20 × 10^6 cells were harvested and lysed. Protein A/G MagBeads pre-coated with 5μg of the antibody of interest (HNRNPA2B1/ILF3, Proteintech) and incubated with cell lysate supernatant overnight at 4°C.The beads containing immunoprecipitated RNA-protein complex were treated with 150μL of Proteinase K buffer to digest the proteins. Specific binding RNAs were isolated by using TRIzol.

2021-11-30 | GSE162303 | GEO

Evaluation the targeted nanobubbles mediated LND against hepatocellular carcinoma by sonodynamic therapy with RNA-Seq

Project description:Sonodynamic therapy is an important approach in the treatment of hepatocellular carcinoma. A novel targeted nanobubbles loaded with HMME and LND was structured as sensibilizer, characterized the properties, and studied therapeutic effect on hepatocellular carcinoma. Next-generation high throughput RNA sequencing (RNA-Seq) was performed to accurately analyze the differential expression of mRNAs and lncRNA targets in hepatocellular carcinoma after sonodynamic therapy.

2022-03-02 | GSE171857 | GEO

Effect of ILF3 on translation during homeostasis and the antiviral response

Project description:Upon detection of viral infections, cells activate the expression of type I interferons (IFNs) and pro-inflammatory cytokines to control viral dissemination. As part of their antiviral response, cells also trigger the translational shutoff response which prevents translation of viral mRNAs and cellular mRNAs in a non-selective manner. Intriguingly, mRNAs encoding for antiviral factors bypass this translational shutoff, suggesting the presence of additional regulatory mechanisms enabling expression of the self-defence genes. Here, we identified the dsRNA binding protein ILF3 as an essential host factor required for efficient translation of the central antiviral cytokine, IFNB1, and a subset of interferon-stimulated genes. By combining polysome profiling and next-generation sequencing, ILF3 was also found to be necessary to establish the dsRNA-induced transcriptional and translational programs. We propose a central role for the host factor ILF3 in enhancing expression of the antiviral defence mRNAs in cellular conditions where cap-dependent translation is compromised. In this dataset we use polysome profiling in combination with RNA-seq to investigate the effect of ILF3 on the translation of mRNAs in HeLa cells in homeostasis and the antiviral response.

2019-10-25 | GSE130742 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data